A detailed history of National Asset Management, Inc. transactions in Bio Atla, Inc. stock. As of the latest transaction made, National Asset Management, Inc. holds 30,000 shares of BCAB stock, worth $10,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,000
Holding current value
$10,200
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 25, 2025

BUY
$0.59 - $2.37 $17,700 - $71,100
30,000 New
30,000 $17,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $12.3M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track National Asset Management, Inc. Portfolio

Follow National Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on National Asset Management, Inc. with notifications on news.